Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis.
Brianna P Matthew, Amir M Hasani, Yun-Ching Chen...
https://pubmed.ncbi.nlm.nih.gov/33549601/Actively Recruiting
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-10-29
2000
Participants Needed
1
Research Sites
N/A
Total Duration
Pulmonary lymphangioleiomyomatosis LAM is a severe lung disease that mainly affects women of childbearing age and currently lacks a fully effective treatment. This research aims to understand how LAM develops at the cellular and molecular levels by identifying proteins and genes involved in lung destruction. The study also seeks to define the clinical course of LAM to support the development of better therapies. Participants diagnosed with LAM may be evaluated every six months or as needed for research purposes. The study uses the Toshiba Aquilion ONE CT device, which provides detailed whole-organ imaging with lower radiation exposure, to assist in examining the lungs. Some participants may include those with tuberous sclerosis complex TSC and pulmonary LAM, as well as non-smoking and smoking control groups without lung disease. During the study, participants undergo clinical assessments including imaging and other tests, while pregnant or nursing women are included but certain procedures involving higher risk or radiation are postponed until after pregnancy or nursing. The main outcome is to define the clinical progression and molecular mechanisms of LAM. Participants contribute by attending evaluations at regular intervals, with the goal of advancing knowledge about LAM over time.
CONDITIONS
Study of the Disease Process of Lymphangioleiomyomatosis
T
Tatyana A Worthy, R.N.
J
Joel Moss, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Heart, Lung, and Blood Institute (NHLBI)
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Ongoing
Participants with LAM undergo evaluations every six months or as needed, including lung imaging with the Toshiba Aquilion ONE CT scanner and clinical assessments. Pregnant or nursing women may have some procedures delayed until after this period.
Visits every six months or as needed
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Brianna P Matthew, Amir M Hasani, Yun-Ching Chen...
https://pubmed.ncbi.nlm.nih.gov/33549601/Brianna P Matthew, Alfredo Lebron, Yun-Ching Chen...
https://pubmed.ncbi.nlm.nih.gov/36930738/Eileen Hu-Wang, John L Schuzer, Shirley Rollison...
https://pubmed.ncbi.nlm.nih.gov/30291925/National Heart, Lung, and Blood Institute (NHLBI)
Lead Sponsor